All In Biotech

Drug Trial Radar · NCT04637828

A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

Cure COVID: A Prospective, Controlled, Randomized Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

Last checked: Nov 19, 2026Latest source record: Jul 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

178

Planned (sponsor's estimate)

Start

Nov 18, 2020

Primary completion

Jul 30, 2021

Study completion Dec 30, 2021

Sponsor

Lead sponsor
Genoscience PharmaIndustry
Sponsor type
Industry
First posted
Nov 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, controlled, randomized phase 2 study designed to evaluate the safety and efficacy profile of GNS561 in patients with COVID-19.

Conditions

  • COVID-19

Interventions

  • GNS561Drug

    study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. number and proportion of participants, per randomized group, with a loss of one or two grades of National Early Warning Score (NEWS2) score at day-7 compared to baselineTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Genoscience Pharma

    Marseille, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.